Multipotent mesenchymal stromal cells (MSCs) are a promising cell type for cell transplantation; however, their utilization remains limited until the availability of adequate alternative sources of MSCs and the thorough understanding of the biology of MSCs isolated from various sources are realized. Fetal lung has been identified as a rich source of MSCs. To explore the therapeutic potential of passaged fetal lung MSCs (FLMSCs), the present study evaluated their growth kinetics, telomere length, karyotype, immunophenotype, and the differentiation potential during in vitro expansion. FLMSCs could be easily amplified in vitro with no significant shorting of telomere length and had a normal karyotype. No significant differences between passage 5 or passage 25 were observed in the immunophenotype analysis using flow cytometry. Moreover, flow cytometry results provided the first demonstration, to our knowledge, that FLMSCs stably expressed pluripotent markers including Oct4, Nanog, Sox2, TRA-1-60, c-Myc, and SSEA-4 through 25 passages. In vitro differentiation studies as identified by confocal microscopy, flow cytometry, RT-PCR, and immunohistochemistry showed that FLMSCs had extended capacity of differentiating into mesodermal, ectodermal, and endodermal lineages, and that their potential for adipogenic, osteogenic, and chondrogenic differentiation may be maintained over 25 passages. Furthermore, osteogenic and chondrogenic differentiation was used as an indicator of their differentiation capability in vivo, as evidenced by ectopic bone and cartilage formation. In summary, these results suggest that FLMSCs are a primitive population and that their extensive in vitro expansion does not involve significant functional modification of the cells, including morphology, growth, karyotype, immunophenotype, and mesodermal differentiation potential. Hence, FLMSCs might constitute an attractive cell resource for cell transplantation to induce regeneration of damaged tissues/organs.
INTRODUCTION
enchymal stromal cells (MSCs) because of their ease of isolation and expansion, multipotency, trophic effects, immunomodulatory properties, and high homing ability Stem cell therapy is currently in use for a wide array of diseases, including leukemia, autoimmune disorders, to damaged tissues (39, 44, 45) . To date, MSCs have been the focus for treating many pathological conditions in cardiovascular disease, and certain bone disorders (26). Great expectations were placed on embryonic stem cells the field of gene therapy, cell transplantation, and regenerative medicine (17,34). (ESCs) for their broad differentiation potential. However, their usage for cellular therapeutics has been ex-MSCs, as recently proposed by the International Society for Cytotherapy, can be defined by three minimal cluded for ethical concerns, imprinting-related developmental abnormalities, and the uncontrollable development criteria: (i) the plastic adherence of the isolated cells in culture; (ii) the expression of CD105, CD73, and CD90 of teratoma in a syngeneic transplantation model (29) . Increasing attention has been drawn to multipotent mes-in greater than 95% of the culture, and their lack expres-sion of markers such as CD45, CD34, CD14, CD11b, ternity, under conditions where it was clear that tissues would otherwise be discarded. This study was approved and HLA class II in less than 2% of the culture; and (iii) the differentiation of the MSCs into osteoblasts, adipo-by the Medical Ethics Review Board of the Chinese Academy of Medical Science and the Peking Union cytes, and chondroblasts in vitro (14) . These criteria are recommended to define the MSCs from adult bone mar-Medical College in compliance with the academic guidelines regarding the use of fetal tissue for research. row (ABM) (14) . In addition to BM, MSCs are also present in other tissues such as cartilage, adipose tissue, Pregnant women gave written informed consent for the use of tissues for research purposes. Fetal gestational dental pulp, placenta, amnion, amniotic fluid, umbilical cord blood, tendon, periodontal ligament, periosteum, age was determined by crown-rump length measurement on ultrasound. synovium, synovial fluid, and in a variety of fetal tissues (3, 8, 10, 16, 21, 31, 37, 38, 43, 48) . Although these various Isolation and Expansion MSC populations share common properties mentioned above, when compared side-by-side they exhibit differ-Using aseptic procedures, the lung was cut into 1-2mm 3 small fragments and digested with 1 mg/ml colla-ences in their gene expression profiles, immunophenotype, and the potential for proliferation and differentia-genase type II (Gibco) for 40 min and with 0.25% trypsin (Invitrogen) for 30 min at 37°C with gentle agitation. tion (29, 46) .
Considering the developmental stage of the fetus, fe-After terminating the trypsin activity with serum and extensive washing of the fragments with phosphate buf-tal stem cells appear to represent an intermediate cell type between embryonic and adult stem cells. It is well fered saline (PBS), all the cell suspensions were used to isolate mononuclear cells by Ficoll gradient centrifuga-documented that fetal MSCs are considered to be immunosuppressive, making them ideal for allogeneic trans-tion (Hao Yang Biological Manufacture Co. Ltd, Tianjin, China). Cell pellets were then resuspended in growth plantation (30) . In addition, fetal MSCs have more amount, faster growth rate, longer telomeres, and greater medium at a density of 5 × 10 4 cells/ml and cultured on fibronectin (Sigma)-coated culture flasks. Growth me-longevity than ABM MSCs (22) . Very recent investigations on fetal MSCs from blood, liver, BM, and aorta-dium was basically the same as that used by Reyes et al. (40) with some modifications and consisted of 60% gonad-mesonephros (AGM) reported that fetal MSCs were able to express pluripotent markers including Oct4, Dulbecco's modified Eagle medium/Ham's F12 medium, 50 U/ml penicillin/streptomycin, 1× insulin trans-Nanog, Sox2, and SSEA-4, and differentiate directionally in vitro into multiple cell lineages (19, 22, 47) . In ferrin selenium (ITS), 2 mM L-glutamine (Gibco), 40% MCDB-201, 10 −8 M dexamethasone (Sigma), 2% fetal light of the above reports, we speculated that fetal lung MSCs (FLMSCs) might have similar properties to MSCs bovine serum (FBS; Hyclone), 50 ng/ml human epidermal growth factor (hEGF), and 10 ng/ml basic fibroblast from other fetal tissues. In the present study, we focused on the biological properties of FLMSCs, including growth growth factor (bFGF; Peprotech). The cells were maintained at 37°C and a humidified 5% CO 2 with growth kinetics, the expression of MSCs and pluripotent markers as well as the differentiation potential. Our data medium changed every 3-4 days, detached when 60-80% confluency using 0.125% trypsin-EDTA (Invitrogen) showed that FLMSCs were easily expandable for clinical relevance and capable of proliferating for 25 pas-and replated at a 1:3 ratio onto noncoated plastic flasks under the same culture conditions to preserve their stem sages without significant telomere shortening. In addition, we demonstrated for the first time that FLMSCs cell characteristics. If necessary two passages were performed in order to obtain a pure population of FLMSCs. were able to express pluripotent markers and differentiate in vitro into cell types of all three germ layers, and
Morphologically, a purity of 95% of the FLMSCs population in the culture flask was considered a pure popula-that FLMSCs showed stable marker expression and steady trilineage mesenchymal differentiation potential tion, a number also confirmed by fluorescence-activated cell scanning (FACS) assay. through 25 passages. Therefore, this study improved our understanding of the biology of FLMSCs and suggested ABM samples were obtained from volunteer donors following informed consent according to a protocol ap-that FLMSCs are a primitive population. FLMSCs might serve as an attractive alternative resource for cell trans-proved by the Medical Ethics Review Board of the Chinese Academy of Medical Science and the Peking Union plantation with potential therapeutic advantages over ABM MSCs.
Medical College. BM mononuclear cells were obtained by Ficoll-Paque density gradient centrifugation (Hao
MATERIALS AND METHODS
Yang, Tianjin, China). Cells were plated at 2 × 10 6 cells/ Ethics cm 2 in growth medium cultured on fibronectin-coated plastic flasks. After 72-96 h of culture, suspended cells Fetal tissues (n = 4) were obtained from women undergoing elective termination of second-trimester (14- 16 were removed and replaced with fresh medium. Medium was changed every 3 days thereafter. MSCs grew as col-weeks) pregnancies in Tianjin Central Hospital of Ma-onies that were detached with 0.1% trypsin-EDTA and to the manufacturer's protocol. FLMSCs at the 5th and 25th passages were plated at a density of 1 × 10 2 on 96-subcultured at a density of 4-8 × 10 3 cells/cm 2 .
Fibroblasts from fetal skin (FSFs) were purchased well culture plates for 1, 2, 3, 4, 5, 6, 7, 8, and 9 days. The growth kinetics were determined by quantifying the from Cell Culture Center of the Peking Union Medical College. FSFs were cultured according to the recom-incorporation of BrdU during DNA synthesis as well as the relative values of different concentration, expressed mended protocol. Briefly, FSFs grew in expansion medium (high glucose) DMEM supplemented with 10% as mean ± SD, and were recorded on the growth curve to reflect the growth characteristics of the cells. FBS and 50 U/ml penicillin/streptomycin and were generally split at a 1:3 ratio.
Cell Cycle Analysis The human ES cell line (kindly provided by HUES Cell Facility/Melton Laboratory, Harvard University/ After being replated, FLMSCs of passages 5 and 25 at the log phase of logarithm growth (days 4 to 7) were HHMI, Cambridge, USA) was maintained in ESC media consisting of KO-DMEM (Invitrogen), 50 U/ml penicil-trypsinized and permeabilized with 70% ethanol at −20°C for at least 24 h, followed by incubation with 50 lin/streptomycin, 1% Gluta-MAX TM (Invitrogen), 1% nonessential amino acids (NEAA, Invitrogen), 0.1% 2-µg/ml RNase A (Sigma) for 20 min at 37°C and in 50 µg/ml propidium iodide (Sigma) for 5 min at room tem-mercaptoethanol (Gibco), 10% KO Serum Replacement (Invitrogen), 10% Plasmanate (Bayer), 10 ng/ml bFGF perature. DNA content was analyzed in a FACScalibur flow cytometer (BD) using MODFIT software (Verity). (with a protein carrier, Peprotech), and 12 ng/ml hLIF (option, Chemicon). The media should be changed every Telomere Length Measurement by Real-Time PCR day. It was important to split subconfluent ESCs before they differentiated. Mouse embryonic fibroblasts (MEFs)
Telomere length was measured on K562 cell line, the 5th and 25th passage FLMSCs genomic DNA (Qiagen) were prepared following the proposed protocol and MEFs media comprised DMEM (Invitrogen), 50U/ml using an ABI 7500 Sequence Detection System (Applied Biosystems). H-globin was used as a control for amplifi-penicillin/streptomycin, and 10% FBS. MEFs were used as a feeder layer and should be plated 1-2 days before cation. Telomere and h-globin primer sequences were as follows: telomere (forward) 5′-CGGTTTGTTTGGGTT thawing/passaging ESCs.
TGGGTTTGGGTTTGGGTTTGGGTT-3′, (reverse) 5′-Karyotyping GGCTTGCCTTACCCTTACCCTTACCCTTACCCT TACCCT-3′; h-globin (forward) 5′-GCTTCTGACAC FLMSCs at the 5th and 25th passages in logarithm growth were treated with colchicine (1 µg/ml) for mi-AACTGTGTTCACTAGC-3′, (reverse) 5′-CACCAAC TTCATCCACGTTCACC-3′. Each 20 µl reaction in-totic arrest and harvested by standard hypotonic treatment and methanol/acetic acid (3:1) fixation. Slides cluded 20 ng DNA, 1× SYBR Green master mix (Qiagen), and 100 nM primers. Amplification conditions were prepared by standard air drying method and stained with 10% Giemsa (Sigma). The karyotypes were ana-were 40 cycles of a two-step PCR (95°C for 15 s, 64°C for 60 s) after initial denaturation (95°C for 10 min). A lyzed by a microscope. Twenty to 30 metaphase cells per culture were analyzed. The karyotype of each culture melting curve analysis was performed in order to control the specificity of the amplification products. Telomere/ is representative of >95% metaphase cells. single copy gene (T/S) values were calculated by 2 −∆∆Ct Colony Forming Unit-Fibroblast (CFU-F) Assay and relative T/S values were generated by dividing sample T/S values with the T/S value of a reference cell line The CFU-F assay was performed according to previously described methods (22) . Briefly, mononuclear DNA (K562). cells isolated from fetal lung were seeded in a 60-cm 2 Flow Cytometry Analysis dish at the density of 0.1-1 × 10 3 cells/cm 2 . After 10 days, the cells were stained with 0.5% crystal violet FACS experiments were performed to investigate the marker profile of FLMSCs (passages 5 and 25) and ABM (Sigma) and positively stained colonies (>50 cells) were counted as CFUs. Cumulative population doubling was MSCs, enduring cryopreservation and thawing well. Cells were trypsinized and resuspended in 0.1% NaN 3 calculated by the following formula: PD = [log 10 (N H ) − log 10 (N I )]/log 10 (2), where PD is population doubling, N I PBS. Cells (1 × 10 5 ) were labeled with fluorescein isothiocyanate (FITC) or phycoerythrin (PE)-labeled anti-represents inoculum number and N H is cell harvest number (7) . human antibodies, including CD11b, CD31, HLA class II, CD45, CD34, CD14, CD117, CD29, CD13, CD90, Cell Proliferation Assay CD44, CD166, CD73, CD49e, CD54, HLA class I, CD106, CD271 (all from BD PharMingen), CD105 (An-Cell proliferation was evaluated by a cell proliferation enzyme-linked immunosorbent assay (ELISA) kit cell), SSEA-4 (R&D), CD133 (Miltenyi), GD2 (BD), CD146 (Chemicon), and STRO-1 (R&D). To detect in-with 5-bromo-2′-deoxyuridine (BrdU; Roche) according tracellular antigens, 2 × 10 5 cells (FLMSCs, ABM MSCs, collagen II was detected by FACS and RT-PCR assays.
Other related genes such as lipoprotein lipase (LPL), FSFs, and ESCs) were fixed with ice-cold acetone for 10 min at room temperature, permeabilized with 0.1% RUNX2, and aggrecan were also examined by RT-PCR. Triton X-100 (Sigma) for 15 min at room temperature, Neural Differentiation and then labeled with the following antibodies: Oct4, Sox2 (R&D), Nanog (eBioscience), c-Myc, TRA-1-60
To induce neuroectoderm differentiation, cells were treated as previously described (30) with modifications. (Chemicon). To eliminate any nonspecific binding, the cells were washed twice with PBS and 2% normal serum Briefly, cells were plated at a density of 20,000 cells/ cm 2 onto fibronectin-coated glass slides in neural induc-for 5 min, then the cells were incubated at the same ratio of fluorochrome/protein for the isotype control and tion media, which consisting of DMEM/F12, 1% penicillin/streptomycin, N2 and B27 supplements (Invitrogen, specific antibody for 30 min at 4°C. Negative controls were stained with isotype-matched FITC or PE-conju-which are two multicomponent cell culture supplements), plus the following conditions: (a) 20 ng/ml EGF, gated IgG or IgM. A total of 10 5 events were acquired and analyzed using FACS Calibur TM flow cytometer uti-10 ng/ml bFGF, and 10 ng/ml platelet-derived growth factor (PDGF; Peprotech) for 7 days; (b) 10 ng/ml lizing CELLQuest acquisition data analysis software (BD). bFGF, 10 ng/ml PDGF, and 50 ng/ml nerve growth factor (R&D) for 7 days. After 14 days, neural marker nes-In Vitro Multipotent Differentiation Assays tin (R&D), microtubule-associated protein 2 (MAP2), NG2, glial fibrillary acidic protein (GFAP) (all from FLMSCs were trypsinized, replated, and cultured on a coverslip in six-well plates 1 day prior to differentia-Chemicon), and oligodendroglial marker O4 (DAKO) were assayed by FACS, confocal microscopy, and RT-tion except pellet cultures for chondrogenesis. FLMSCs under growth conditions were used as negative control.
PCR.
Hepatogenic Differentiation Adipogenic, Osteogenic, and Chondrogenic Differentiation
The induction procedure was as follows: (a) 10 ng/ ml bFGF + 20 ng/ml recombinant human hepatocyte FLMSCs at the 5th and 25th passages were cultured in adipogenic, osteogenic, and chondrogenic media for growth factor (Peprotech) + 1× ITS for 14 days; (b) 10 ng/ml bFGF + 30 ng/ml Oncostatin M (R&D) + 1× ITS 3 weeks. The differentiation media were as follows: (a) adipogenic medium consisting of 1 µM dexamethasone, for 14 days. We evaluated the mRNA and protein expression of hepatic-specific markers albumin and cyto-0.5 mM isobutyl-methylxanthine, 100 µM indomethacin, and 10 µg/ml insulin (all from Sigma); (b) osteoge-keratin 18 (CK18) by FACS, confocal microscopy, and RT-PCR. The mRNA expression of αFP was also de-nic medium comprising 0.1 µM dexamethasone, 10 mM β-glycerophosphate, and 50 µM ascorbic acid (all from tected by RT-PCR analysis. Hepatocyte function was assessed by dosing albumin in culture supernatants and Sigma); (c) chondrogenic medium including 1× ITS, 1× linoleic acid-bovine serum albumin (Sigma), 100 nM detecting glycogen by periodic acid schiff (PAS) staining. dexamethasone, 50 µg/ml ascorbate 2-phosphate (Sigma),
In Vivo Bone-Forming Assay and 10 ng/ml transforming growth factor-β1 (TGF-β1; R&D). The differentiation media were replaced every Approximately 1 × 10 7 FLMSCs (passage 5) was mixed with 40 mg of hydroxyapatite/tricalcium phos-3-4 days. Induced cells were stained with Oil Red O, Alizarin Red S, and Alcian Blue for lipid droplets, cal-phate (HA/TCP) powder (60% HA and 40% TCP; 200-300 µm pore size; Sichuan University, China) at 37°C cium deposition, and proteoglycan deposition, respectively. Confocal microscopy assessed the expression of rotated for 90 min. A secondary matrix was formed by mixing 15 µl of mouse fibrinogen (3.2 mg/ml) and 15 adipocyte-specific marker peroxisome proliferator activated receptor-γ2 (PPAR-γ2) and osteocyte-specific marker µl of mouse thrombin (25 U/ml; Sigma) to form a solid fibrin gel of about 25 mm in diameter. The mixtures osteocalcin, while immunohistochemistry assayed the expression of chondrocyte-specific marker collagen II.
were immediately transplanted SC into the dorsal and orofacial surface of 8-week-old female immunocom-For immunohistochemical study, human-specific collagen II antibody (dilution 1:50; Santa Cruz) was used as promised beige nude mice (NIH-bg-nu/υ-xid; Institute of Experimental Animal, Beijing, China) as previously the primary antibody. The sections of cell pellets were then stained with secondary antibodies coupled with described (1). For controls, the same amount of HA/TCP powder without cells was transplanted SC in an identical horseradish peroxidase and reactions were visualized by adding 3,3-diaminobenzidine (DAB, Sigma). Counter-fashion. Surgical procedures were performed in accordance with specifications of an approved institutional staining was performed with hematoxylin (Sigma). In addition, the expression of PPAR-γ2, osteocalcin, and small animal protocol. The animals were randomly di-vided into experimental and control groups (n = 6 for lution 1:350; Chemicon), TRA-1-60 (dilution 1:350; Chemicon). Primary antibodies were developed with each group) and each mouse received three implants. The implants were harvested at 8 weeks posttransplanta-corresponding secondary FITC or PE antibodies at a concentration of 1:500 for 1 h at room temperature. tion, fixed in 4% buffered paraformaldehyde for 2 days, followed by 1 day in 20% sucrose, decalcified, and then Cells were incubated for 1-2 h at 37°C with humanspecific SSEA-4 (dilution 1:200; R&D). 4,6-Diamidino-frozen in liquid nitrogen. The implants were cut to into 5-µm sections and stained by hematoxylin and eosin 2-phenylindole (DAPI; Vector Laboratories) was used to counterstain the nucleus. Coverslips were transferred (H&E) as well as in von Kossa (3% AgNO 3 ) for bone formation. Expression of osteocalcin was analyzed with to glass coverslides and examined on a TCS-SP2 confocal laser-scanning microscopy (Leica). A dual-band flu-a specific goat anti-human osteocalcin antibody (Santa Cruz) at 4°C overnight and rabbit anti-goat IgG (South-orescence filter set at FITC (or PE)/DAPI was used for acquisition of images in both fluorescence channels. ern Biotechnology Associates) was used as a secondary antibody.
RT-PCR In Vivo Cartilage-Forming Assay
Undifferentiated FLMSCs and various induced cells were prepared to extract total RNA using Trizol (In-The cultured FLMSCs were resuspended at a density vitrogen) according to the manufacturer's protocol. All of 1 × 10 7 /ml in 2% low-viscosity alginate (Sigma) in RNA samples were DNA free. Total RNA was reverse-0.9% NaCl. The alginate/cell suspension was dripped transcribed to cDNA with the use of SuperScript III slowly to a 100 mM CaCl 2 solution at room temperature first-strand synthesis system (Gibco). For each PCR refor 30 min of polymerization, then the alginate was action, 20 ng of cDNA template was used in a 25-µl gelled. One milliliter of alginate gel mixed with or withreaction volume with HotStar Taq (TaKaRa). The amout FLMSCs was immediately implanted into subcutaplified products were identified by size on a 1.5% agarneous pockets on the dorsum surface of 8-week-old ose gel (Gene Tech) and stained with ethidium bromide nude mice (n = 6 for each group). After 8 weeks, the (Sigma). β-Actin was used as a control. Primers and the mice were anesthetized, and then the constructs were annealing temperatures are listed in Table 1 . carefully separated from the surrounding fibrous capsule and immediately stored in liquid nitrogen. Besides H&E, Statistical Analysis sections (5 µm) were stained with Alcian Blue to visual-Results were calculated for our data and presented as ize proteoglycans. The expression of collagen II in the mean ± SD where indicated. Statistical significance was sections was detected by goat anti-human specific antidefined as p < 0.05 using Student's t-test or analysis of body.
variance (ANOVA). The t-test was used after ANOVA In Vivo Teratoma Formation Assay to determine where the significance difference lies, and then Bonferroni correction was used for the adjustment According to recent studies by Kishi (28) , approxifor multiple comparisons. mately 1 × 10 7 FLMSCs (passage 5) were injected intramuscularly into the dorsal flank of 8-week-old nonobese RESULTS diabetic-severe combined immunodeficiency (NOD-SCID)
Biological Properties of FLMSCs mice under anesthesia. The same volume of PBS was injected in the control group (n = 6 for each group). At FLMSCs were isolated from fetal lungs and expanded in vitro. After enzymatic digestion and growth 8 weeks postinjection, no tumor was found in either experimental and control groups.
in the plastic flask for 48 h, adherent cells exhibited heterogeneity: one having fibroblastoid morphology and Confocal Microscopy the other with a more round appearance. Round cells rapidly disappeared with passaging and adherent cells Adherent to glass coverslips, cells were fixed with ice-cold acetone and permeabilizated in 0.1% Triton X-showed similar spindle-shaped morphology after the second passage. After 2 weeks, spindle-shaped cells 100. Cells were incubated overnight at 4°C with primary human-specific antibodies such as PPAR-γ2 (dilution 1:
reached confluence with a whirlpool-like appearance at the low-power magnification (Fig. 1A) . FLMSCs were 300), osteocalcin (dilution 1:300), collagen II (dilution 1:80; Santa Cruz), nestin (dilution 1:700; R&D), O4 (di-passaged at a dilution of 1:3 and reached confluence within 2-3 days. Then the passage procedures were re-lution 1:700; DAKO), MAP2 (dilution 1:750), GFAP (dilution 1:800), NG2 (dilution 1:300; Chemicon), albu-peated and some cells had been cryopreserved in liquid nitrogen before they were thawed and cultured. At pas-min (dilution 1:250), CK18 (dilution 1:150; Santa Cruz), Oct4 (dilution 1:200; R&D), Sox2 (dilution 1:200; sage 25, FLMSCs maintained their spindle morphology ( Fig. 1B) and a normal karyotype of 46, XX (Fig. 1C ). R&D), Nanog (dilution 1:350; eBioscience), c-Myc (di- No euploidy was found in per culture and no aneuploidy ogy. FLMSCs proliferated much more rapidly than ABM MSCs (data not shown). The results of the BrdU in P5. Aneuploidy in P25 was less than two percent. The growth kinetics of FLMSCs was reflected by CFU-F, incorporation assays were recorded on the growth curve that displayed 'S" type ( Fig. 1E ). After being replated, BrdU incorporation, and cell cycle assays. For calculating the starting number of MSCs in the mononuclear FLMSCs had an adaptive phase, then began to expand rapidly and move into a log phase of logarithm growth. cell fraction, CFU assays were performed and the colonies were 29.4 ± 5.26/1000 cells (Fig. 1D ). FLMSCs pre-At the eighth day, the cell number reached the highest level and cell growth was in a plateau phase. To confirm sented an average population doubling time of 31.01 ± 1.95 h and the growth rate remained stable through 25 proliferation-related observations, an analysis of cell cycle status was performed by measuring DNA content passages (about 60 population doublings). We observed that FLMSCs in the present study could withstand about using flow cytometry. Flow cytometric analysis of cell cycle phase revealed that more than 90% of the cells 25, 28, 30, and 33 passages without obvious decline in proliferation ability and significant changes in morphol-were at G 0 /G 1 and only a small proportion of cells ac-tively proliferated (Fig. 1F) . The growth pattern of markers were similar to the phenotype of MSCs suggested by the International Society for Cytotherapy (14), FLMSCs was consistent with the results demonstrated by Guo and colleagues (23) . Real-time PCR demon-except that the expression of STRO-1, CD271, and CD106 was lower than ABM MSCs. The expression of strated that there was no significant difference between passage 5 (relative value: 10.41 ± 3.33) and passage 25 GD2, a recently suggested marker for MSCs, was in conformity with the previous study (32) . The rate of po-(relative value: 6.67 ± 0.74) in the length of telomere, in spite of a trend for a decrease after 25 passages ( Fig.  sitivity for CD146 was similar to other fetal organs and lower than ABM MSCs as well as pericytes (11, 22) . 1G). In short, FLMSCs were plastic-adherent cells with spindle-shaped morphology, great proliferation poten-This might be relevant to their negative expression of STRO-1 and the different MSCs source (3, 22) . More-tial, and a normal karyotype. Moreover, these properties could be maintained up to 25 passages. over, flow cytometry analysis was used to determine the expression of pluripotent markers in FLMSCs (passages Stability of the Marker Profile of FLMSCs During 5 and 25), FSFs, and ESCs (positive control), though no Long-Term Expansion consistent data indicated that MSCs expressed pluripotency markers. FLMSCs were found to express high Flow cytometry was used to monitor the marker profile of morphologically homogenous FLMSCs (P5 and level of Oct4, Nanog, Sox2, c-Myc, and TRA-1-60, and moderate level of SSEA-4 ( Fig. 2A) . Confocal micros-P25) as well as ABM MSCs. Between the two passages of FLMSCs, the expression levels of the examined copy confirmed their subcellular localization in the nuclei (Oct4, Nanog, Sox2, c-Myc, and TRA-1-60) or markers were stable during the long expansion period. More than 95% of the MSC population expressed CD44, cytomembrane (SSEA-4) of FLMSCs (Fig. 2B ). Specifically, out data indicated that there was no significant CD29, CD73, CD90, CD13, CD49e, CD105, CD166, and HLA class I, whereas FLMSCs moderately ex-difference in ESCs marker expression between the two passages of FLMSCs. Altogether, FLMSCs showed sta-pressed CD54, CD146, and GD2. By contrast, these cells lacked expression (≤2% positive) of CD45, CD34, ble expression level of MSCs and pluripotent markers even after ex vivo long-term expansion and enduring CD14, CD117, CD11b, CD31, CD106, CD133, CD271, STRO-1, and HLA class II ( Table 2 ). The examined cryopreservation and thawing. FSFs negatively ex- tive Oil Red O staining showed lipid vacuole formation in both experimental passages of cells (Fig. 3Ai ). In noninduced FLMSCs (Fig. 3B-D) . However, the ex- in negative controls ( Fig. 3B-D) .
To determine chondrogenic differentiation, FLMSCs (passages 5 and 25) were pelleted and incubated in pressed these pluripotency markers, while ESCs were strongly positive for the detected pluripotency markers chondrogenic medium. Cell pellets increased in size due to production of extracellular matrix. Thin sections of ( Fig. 2A) .
the pellets were positively stained with Alcian Blue (Fig.  Extended Differentiation Potential for Mesodermal, 3Aiii) for sulfated proteoglycan in extracellular matrix.
Ectodermal, and Endodermal Lineages
Compared with control cells (Fig. 3B-D) , more than 90% of cells were positive for collagen II as assessed A well-established hallmark of MSCs is their trilineage mesenchymal differentiation, but MSCs from by flow cytometry (Fig. 3B ) and the increasing expression of chondrocyte-specific genes such as aggrecan and other tissues have been reported to possibly differentiate, though controversial, into nonmesodermal cells (2) . collagen II was revealed by RT-PCR analysis (Fig. 3D ). Immunohistochemical analysis also confirmed the ex-The observation that FLMSCs expressed pluripotent markers prompted us to study whether FLMSCs had pression of collagen II in the induced cell pellets, whereas in control pellets, only a high-density cell layer greater differentiation potential to give rise to diverse cell types of all three germ layers. In order to verify was observed ( Fig. 3Ciii ). Together, these results confirmed the trilineage mesenchymal differentiation of the possibility, we investigated their differentiation into mesodermal, ectodermal, and endodermal lineages by FLMSCs, which could be maintained over 25 passages. culturing them in specific induction media as described Neuroectodermic Differentiation above.
To induce neural differentiation, FLMSCs were cul-Mesodermal Differentiation: Adipogenesis, tured in classical serum-free medium (DMEM/F12 sup-Osteogenesis, and Chondrogenesis plemented with N2 and B27), which was suitable for neural stem cells. At the end of the induction period, the To evaluate the adipogenic differentiation, FLMSCs at passages 5 and 25 were subjected to induction in adi-majority of the cells reduced proliferation, acquired a neuronal morphology of the long cell process, and were pogenic medium and resulted in cell growth arrest. Posi- strongly stained with the neuronal lineage marker pressed nestin. The mRNA expression of these markers was observed by RT-PCR (Fig. 4E ). In addition, a con-MAP2, the neural progenitor marker nestin, and the neural marker NG2 (Fig. 4A) . Likewise, FACS analysis of siderable portion of cells differentiated into glial cells. They maintained a flattened morphology and were posi-MAP2, nestin, and NG2 expression showed that the positive cells were increased from 0.19 ± 0.26%, 21.92 ± tive staining for the classical glial fibrillary acidic marker GFAP as well as oligodendroglial marker O4 0.45%, and 0.16 ± 0.77% in control cells to 99.47 ± 1.23%, 99.52 ± 0.91%, and 93.52 ± 0.59% in induced (Fig. 4C) . Flow cytometry experiments revealed that differentiated cells expressed increasing amounts of mark-cells, respectively (Fig. 4B) , although control cells ex- ers compared with FLMSCs (Fig. 4D ). PCR analysis cytoplasmic volume with an elliptical shape. For the purpose of further confirming efficient hepatic induc-further confirmed the elevated expression level of GFAP (Fig. 4E ). Our flow cytometry data suggested that a frac-tion, we assessed the expression of hepatocyte-specific markers within these cells on the protein or mRNA tion of differentiating cells might coexpress the neuronal and glial markers, which was consistent with Beltrami level. Mature hepatocyte markers such as albumin and CK18 were positively stained as visualized by confocal et al.'s results (6) . Thus, these data demonstrated that FLMSCs were successfully induced to neuronal and microscopy (Fig. 5A ). FLMSCs cultured in growth medium did not stain with albumin and CK18 antibodies glial cells, which verified their ectodermal differentiation capacity. (Fig. 5A) . The positive percentages for albumin and CK18 in the induced cells were 91.75 ± 1.15% and Endodermal Hepatocyte Differentiation 63.94 ± 0.39%, respectively, while the positive percentages in control cells were very low for albumin (0.57 ± To verify the ability of FLMSCs to generate endodermal derivatives, we assayed these cells for hepatic dif-0.19%) and CK18 (0.43 ± 0.25%) (Fig. 5B ). In addition to albumin and CK18, RT-PCR analysis also confirmed ferentiation. After induction, FLMSCs exhibited a larger the mRNA expression of the early endoderm differentia-FLMSCs directly differentiated in vitro cell type of all three germ lineages. tion marker αFP (Fig. 5C ). Afterwards, we examined whether hepatocytes derived from FLMSCs were func-Assessment of Bone and Cartilage Formation as Well tionally competent. These cells displayed the ability to as Tumor Formation Following In Vivo Implantation store glycogen as demonstrated by PAS staining, while no staining was noticed in negative control (Fig. 5D) .
To demonstrate functional role of FLMSC-mediated new bone formation, expanded FLMSCs with HA/TCP Moreover, we evaluated their abilities to produce albumin as tested by dosing the concentration in culture su-powder as their carrier were transplanted subcutaneously into the dorsal and orofacial regions of the immunocom-pernatants. Our data demonstrated that the level in the supernatant of induced cells (0.702 ± 0.103 g/L) was promised mice, resulting in a considerable alteration of the dorsal and orofacial outline (Fig. 6A) . Histologic significantly higher compared with control (0.083 ± 0.117 g/L) (Fig. 5E ). Therefore, these findings con-analyses 8 weeks after transplantation revealed the existence of newly formed bone tissue in the vicinity of the firmed that FLMSCs-derived hepatocyte-like cells had similar expression pattern of hepatocyte-specific mark-scaffold that was the source of calcium and phosphorus for mineralization, consistent with a recent report (35) . ers and exhibited liver-specific functions similar to human hepatocytes. In summary, we demonstrated that Bone tissue characterization was displayed by H&E staining (Fig. 6Bi ) as well positive von Kossa staining formation, FLMSCs were seeded into three-dimensional alginate constructs and implanted subcutaneously into (Fig. 6Bii ) for mineral deposition. Analysis of humanspecific osteocalcin by confocal microscopy confirmed the dorsal regions of nude mice (Fig. 6C ). After 8 weeks posttransplantation, the volume of the implants was the presence of human cells undergoing bone differentiation. Osteocalcin-positive cells were always seen in the about 50-60% of the initial size due to being capsuled by connective tissues and not tightly attached to the sur-vicinity of the scaffold, as expected for physiologic bone formation (Fig. 6Biii) . Conversely, bone formation was rounding tissues. Histochemical analysis of the implants showed H&E staining (Fig. 6Di ; the upper row) as well not observed in HA/TCP particle transplants that received scaffold only (no cells), with only some sporadic as positive Alcian Blue (Fig. 6Dii ; the upper row) staining for neo-cartilage. There were substantial amounts of cell infiltration (Fig. 6Bi-iii) . Hence, these data indicated that FLMSCs had a capability of forming new alginate-containing cells encased in cartilage lacuna, which was looser than a genuine cartilage matrix ( Fig.  bone in vivo transplantation and suggested a practical potentiality for cell therapy for disorders of bone. 6Di, ii). Moreover, samples were fixed and immunostained positively for the cartilage-specific marker of To examine the potential of FLMSCs for cartilage collagen II with human-specific antibody as confirmed were injected into NOD-SCID. After 8 weeks, injected FLMSCs were absorbed and no evidence of tumor for-by confocal microscopy (Fig. 6Diii) , which was consistent with the results of Cai and coworkers (9) . As a re-mation was found. The finding revealed that the transplantation of FLMSCs for cell-based therapies involved sult, we verified the differentiation potential of FLMSCs to form cartilage in vivo.
little risk of tumor formation. Taken together, we demonstrated that FLMSCs were capable of mediating bone To test the ability of FLMSCs to form tumor, cells and cartilage formation and had little risk for tumor for-sential. Consequently, whether the differences between fetal and adult MSCs could be attributed to the specific mation.
culture conditions used need further studies.
DISCUSSION
FLMSCs in the present study were plastic-adherent and spindle-shaped cells that rapidly proliferated in cul-MSCs are presently the most promising cell source for therapeutic applications. To date, most of what we ture, though they exhibited a finite lifetime (over 60 population doublings) and did not display properties of know about MSCs has been derived from work on ABM MSCs. The expression of pluripotent markers in ABM immortalized cells. MSCs were reported to be passaged in vitro for a limited period, usually about 8-15 pas-MSCs and their differentiation towards extramesodermal lineages are still a highly controversial issue, but a de-sages, equivalent to 25-40 population doublings, before they stopped proliferation and began to degenerate (24) . crease in differentiation capacity as well as stem cell number with increasing donor age has greatly limited Notwithstanding, our data indicated that FLMSCs were able to be cultured for at least 25 passages without sig-their utilization (49) . This prompts researchers to look for alternative sources of MSCs. Many studies have re-nificant telomere shortening and maintain morphology as well as a normal karyotype after ex vivo long-term vealed that there is an optimal amount of MSCs in the second-trimester fetus (25, 36) . Our previous studies expansion, which was associated with the ability to selfrenew, which proved them preferable for cell transplan-have shown that MSCs from fetal lung meet the putative definition of MSCs and possess the neural differentia-tation and tissue regeneration (33) . Cell cycle status revealed the existence of a large percentage (>90%) of tion potential (15) . Recently, it has been demonstrated that MSCs from many fetal tissues express pluripotent quiescent cells (G 0 /G 1 ) along with a smaller population (<10%) of proliferating cells, which was consistent with markers such as Oct4, Nanog, Sox2, and SSEA-4 (19, 22, 47) . Moreover, the expression of pluripotent their stem cell characteristics and suggested the active proliferation of the small subset so as to maintain the markers Oct4, Nanog, and Sox2 may be retained to 17 passages (19). In line with these results, our results con-great growth rate of the whole population (15) . FACS analysis indicated that the marker panel of firmed that FLMSCs could express pluripotent markers Oct4, Nanog, Sox2, TRA-1-60, c-Myc, and SSEA-4, FLMSCs were comparable to the phenotype of MSCs on the basis of the studied markers (CD44 + , CD29 + , CD73 + , and have the extended differentiation potential to give rise to cell types of all three germ layers. More impor-CD90 + , CD13 + , CD49e + , CD105 + , CD166 + , CD54 + , HLA-class I + , and CD45 − , CD34 − , CD14 − , CD117 − , tantly, FLMSCs showed stable expression of MSCs and pluripotent markers and maintained in vitro potential for CD11b − , CD31 − , CD133 − , HLA-class II − ) (14). However, some antigens that expressed on ABM MSCs appeared trilineage mesenchymal differentiation to at least 25 passages, which suggested the additional advantages of not to be expressed on cultured fetal lung cells (i.e., STRO-1, CD271, and CD106). Although STRO-1 was FLMSCs over ABM MSCs for cell transplantation.
Therefore, these studies might support and extend a marker used to isolate MSCs from BM, some ABM MSCs did not express STRO-1 (18) . The negative ex-previous findings demonstrating the therapeutic potential of fetal MSCs for human use. Ontogeny (fetal vs.
pression of CD271 might be relevant to culture because CD271 was lost during culture (32) . As for CD106, adult) might be one reason for these differences between fetal and adult MSCs. Since 2002, numerous papers in ABM MSCs were positive, while MSCs from fetal BM and lung negatively expressing CD106, so its expression the literature have described MSC-like cell cultures, or even cell lines, in adult and fetal tissues and named me-might be ontogeny related (25). Additionally, FLMSCs expressed elevated level of novel surface markers GD2 sodermal progenitor cells (MPCs) (40), multipotent adult progenitor cells (MAPCs) (27), AFS (12), marrow-and CD146 in line with recent findings (11, 22, 32) . Special attention should be paid to the expression of HLA isolated adult multilineage inducible cells (MIAMI cells) (13), etc. Many of them reported to express Oct4 class II in FLMSCs, because HLA class II is related to the immune rejection during allogeneic transplantation. have the ability to generate cells of multiple germinal layers, including mesenchymal cells as well as neuroec-Their lack of expression of HLA class II indicated the minimal risk of alloreactivity in cell transplantation, and toderm-like cells (41). It remains unclear whether these cell populations exist in vivo, or are a cell phenotype implied the potential for allogenic delivery in immuocompetent patients. Surprisingly, expanded FLMSCs induced by culture. In the culture conditions, FBS has been used in most studies, whose concentrations usually continued to express MSCs markers at similar levels through 25 culture passages. Under controlled condi-vary between 2% and 20% (24) . Because of the highly variable culture conditions among different laboratories tions, FLMSCs were able to differentiate in vitro into osteogenic, adipogenic, and chondrogenic lineages as and a marked impact of specific culture media on MSC cultures (24), standardized MSC preparations will be es-demonstrated by histochemical staining and by the RNA and protein expression of lineage-specific markers. Ex-tivate FLMSCs might not be one reason for the expression of pluripotent markers in FLMSCs. It is worthwhile panded ABM MSCs often encountered with a decline in differentiation potential with extended passaging as to find the explanation for this phenomenon. The expression of pluripotent markers were indicative that FLMSCs demonstrated by Banfi and coworkers (4) . However, the present study showed that FLMSCs retained their trili-might possess the potential to differentiate into cell types derived from all three germ layers. Then differentiation neage mesenchymal differentiation potential over 25 passages. Taken together, FLMSCs met the currently studies were carried out to confirm the extended differentiation capability of FLMSCs. recommended criteria to define MSCs and successfully maintained their undifferentiated phenotype in long-term Although our group had previously showed the neuronal differentiation of MSCs from fetal lung (15) , this culture. In the future, it would be necessary to determine whether the long-lived MSCs population were due to study was the first evidence that FLMSCs could differentiate in vitro into glial cells and hepatocytes. In conse-differences in source of origin (lung vs. BM) or resulted from the culture conditions. quence, our data suggested that the differentiation potential of FLMSCs far exceeded that of ABM MSCs. The Pluripotency markers have been considered as a hallmark of ESCs. However, flow cytometry analysis con-multipotency of MSCs has understandably aroused great interest in the ability of MSCs to differentiate into tissue firmed that FLMSCs also expressed pluripotent markers, which consequently set them apart from ABM MSCs. cells in vivo for the therapeutic treatment of various pathologies. It has recently been suggested that stemness A few recent reports suggested that early human MSCs expressed some pluripotency markers. Fetal AGM ex-of MSCs should also be defined as the ability to form ectopic bone in vivo (20) . In the present study, FLMSCs pressed Oct4 and Nanog, while first-trimester fetal MSCs were reported to express Oct4, Nanog, Rex-1, were found to form ectopic bone and cartilage using currently available HA/TCP and alginate, respectively, SSEA-3, SSEA-4, TRA-1-60, and TRA-1-81 (22, 47) . Fetal MSCs from second-trimester BM expressed Oct4, which might be a great promise on the potential use of FLMSCs in bone regeneration and cartilage repair. Nanog, SSEA-4, and Sox2 (19). In addition to Oct4expressing MSCs from amniotic fluid, placenta-derived
In conclusion, the present study improved understanding the biology of FLMSCs by demonstrating their MSCs could be induced to express Oct4, Nanog, and SSEA-4 (5, 38) . Therefore, the expression of pluripotent self-renewal properties, stable MSCs, and pluripotent marker profile as well as extended differentiation capa-markers in fetal lung might also be possible in view of the earlier developmental origin. In this study, we con-bility. Therefore, our data showed that FLMSCs were a primitive cell population. In addition, FLMSCs were firmed that the protein expression of Oct4, Nanog, Sox2, c-Myc, and TRA-1-60 was present in more than 90% of capable of forming ectopic bone and cartilage in vivo, which might facilitate the further research and applica-FLMSCs as evaluated by FACS. It was reported that key to the ESCs-like nature was the expression of Oct4, tion in the clinical restoration of simultaneously damaged bone and cartilage. Taken together, these properties Sox2, Nanog, c-Myc, and Klf4 (42) . Therefore, we proposed that the nature of FLMSCs might be somewhat of FLMSCs made them as attractive candidates for studying and comparing self-renewal and differentiation similar, though not identical, to that of ESCs. The expression of Oct4, Nanog, and Sox2, as Gonzalez and mechanisms in MSCs from different origins, for cell transplantation, or for in vitro drug screening. However, coworkers proposed (19), might be one explanation for the high proliferative potential of FLMSCs for 25 pas-future efforts are necessary to explore their biology in vivo. sages. Although surface expression of SSEA-4 was not as strong as the other markers, the expression of SSEA- 
